AL-S Pharma Company
AL-S Pharma AG develops AP-101, a human monoclonal antibody targeting misfolded SOD1 for the treatment of ALS.
Headquarters:
Schlieren, Zurich, Switzerland, Europe
Employee Number:
1-10
Industry:
Cell, Gene & Biologics Therapeutics
Founded Date:
2016-01-01
Super Industry:
Biopharma & Life Science Tools
Investors:
Neurimmune Holding, TVM Capital Life Science
Ipo Status:
private
City:
Schlieren
Region:
Zurich
Country:
Switzerland


